Levosimendan: A New Therapeutic Option in the Treatment of Primary Graft Dysfunction After Heart Transplantation

被引：18

作者：

Weis, Florian ^{[2
]}

Beiras-Fernandez, Andres ^{[1
]}

Kaczmarek, Ingo ^{[1
]}

Sodian, Ralf ^{[1
]}

Kur, Felix ^{[1
]}

Weis, Marion ^{[2
]}

Schmoeckel, Michael ^{[1
]}

Reichart, Bruno ^{[2
]}

机构：

[1] Univ Munich, Univ Hosp Grosshadern, Dept Cardiac Surg, D-81377 Munich, Germany

[2] Univ Munich, Univ Hosp Grosshadern, Dept Anesthesiol, D-81377 Munich, Germany

来源：

JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2009年 / 28卷 / 05期

关键词：

ACUTE MYOCARDIAL-INFARCTION; CARDIAC ALLOGRAFT; MECHANICAL SUPPORT; FAILURE; LACTATE; HYPOXIA;

D O I：

10.1016/j.healun.2009.01.017

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Primary graft dysfunction after heart transplantation is a severe complication generally related to prolonged ischemia time, size mismatch, or poor quality of the organ. Current therapeutic options include pharmacologic inotropic support with catecholamines or phosphodiesterase inhibitors, and mechanical circulatory support. We report 12 patients who received levosimendan, a new Ca2+ sensitizer, as adjunctive inotropic support. The patients showed a rapid reduction of the doses of inotropic drugs, and no patient needed mechanical support. Levosimendan may be a useful, adjunctive inotropic drug in the treatment of patients with primary graft dysfunction after heart transplantation. J Heart Lung Transplant 2009;28:501-4. Copyright (C) 2009 by the International Society for Heart and Lung Transplantation.

引用

页码：501 / 504

页数：4

共 25 条

[1] Donor myocardial HIF-1α is an independent predictor of cardiac allograft dysfunction:: A 7-year prospective, exploratory study
Aharinejad, S.
Schaefer, R.
Krenn, K.
Zuckermann, A.
Schneider, B.
Neumann, F.
Paulus, P.
Wieselthaler, G.
Wolner, E.
Grimm, M.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (08) : 2012 - 2019
[2] Levosimendan: current status and future prospects
Archan, Sylvia
Toller, Wolfgang
[J]. CURRENT OPINION IN ANESTHESIOLOGY, 2008, 21 (01) : 78 - 84
[3] Levosimendan treatment after primary organ failure in heart transplantation: A direct way to recovery?
Beiras-Fernandez, Andres
Weis, Florian C.
Fuchs, Herbert
Meiser, Bruno M.
Reichart, Bruno
Weis, Marion
[J]. TRANSPLANTATION, 2006, 82 (08) : 1101 - 1103
[4] Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy
Guarracino, F.
Cariello, C.
Danella, A.
Doroni, L.
Lapolla, F.
Stefani, M.
Baldassarri, R.
Vullo, C.
[J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2007, 51 (09) : 1217 - 1224
[5] Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis
James, JH
Luchette, FA
McCarter, FD
Fischer, JE
[J]. LANCET, 1999, 354 (9177) : 505 - 508
[6] Mechanical support for the failing cardiac allograft: A single-center experience
Kavarana, MN
Sinha, P
Naka, Y
Oz, MC
Edwards, NM
[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2003, 22 (05) : 542 - 547
[7] Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation
Lima, Brian
Rajagopal, Keshava
Petersen, Rebecca P.
Shah, Ashish S.
Soule, Beth
Felker, G. Michael
Rogers, Joseph G.
Lodge, Andrew J.
Milano, Carmelo A.
[J]. CIRCULATION, 2006, 114 : I27 - I32
[8] Hypoxia is not the sole cause of lactate production during shock
Luchette, FA
Jenkins, A
Friend, LA
Su, CH
Fischer, JE
James, JH
[J]. JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2002, 52 (03): : 415 - 419
[9] Does epinephrine explain hyperlactatemia in cardiogenic shock?
Luchette, FA
James, JH
Fischer, JE
[J]. CRITICAL CARE MEDICINE, 2001, 29 (09) : 1848 - 1848
[10] Early mortality after cardiac transplantation: Should we do better?
Luckraz, H
Goddard, M
Charman, SC
Wallwork, J
Parameshwar, J
Large, SR
[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (04) : 401 - 405

← 1 2 3 →